AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. decreased its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 85.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,184 shares of the biotechnology company's stock after selling 272,059 shares during the period. Federated Hermes Inc. owned about 0.15% of AnaptysBio worth $598,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in shares of AnaptysBio by 191.4% during the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company's stock valued at $1,130,000 after acquiring an additional 22,164 shares during the last quarter. Victory Capital Management Inc. raised its stake in AnaptysBio by 41.0% in the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock valued at $4,428,000 after purchasing an additional 97,200 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in AnaptysBio in the 4th quarter valued at $311,000. Vanguard Group Inc. boosted its stake in AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock worth $24,411,000 after purchasing an additional 143,584 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of AnaptysBio by 3.0% during the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company's stock worth $15,594,000 after buying an additional 13,336 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Johnson Rice reiterated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Wells Fargo & Company lifted their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. HC Wainwright reiterated a "neutral" rating and issued a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. JPMorgan Chase & Co. lifted their price target on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, Guggenheim reiterated a "buy" rating on shares of AnaptysBio in a report on Monday, March 3rd. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $33.63.

AnaptysBio Stock Up 4.7 %

NASDAQ ANAB traded up $0.96 on Tuesday, reaching $21.58. The stock had a trading volume of 795,423 shares, compared to its average volume of 595,954. The stock has a fifty day moving average price of $17.93 and a two-hundred day moving average price of $19.78. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31. The firm has a market capitalization of $661.79 million, a price-to-earnings ratio of -3.55 and a beta of -0.09.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts' consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $43.11 million during the quarter, compared to analysts' expectations of $10.17 million. Sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its Board of Directors has authorized a share repurchase plan on Monday, March 24th that allows the company to repurchase $75.00 million in shares. This repurchase authorization allows the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.